Wei Huang

Dr. Wei Huang

Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
ZZZhongkai Zhu
Zhongkai Zhu
DGDureti Godana
Dureti Godana
ALAiling Li
Ailing Li
BRBianca Rodriguez
Bianca Rodriguez
CGChenxin Gu
Chenxin Gu
JCJIWANG CHEN
JIWANG CHEN
Echocardiography, a non‐invasive and cost‐effective method for monitoring cardiac function, is commonly used for evaluation and pre‐clinical diagnostics of pulmonary hypertension (PH). Previous echocardiographic studies in experimental models of PH are fragmentary in terms of the evaluation of right ventricle (RV) function. In this study, three rodent models of PH: a mouse model of hypoxia‐induced PH, a rat model of hypoxia+Sugen induced PH and a rat model of monocrotaline‐induced PH, were employed to measure RV fractional area change (RVFAC), RV free wall thickness (RVFWT), pulmonary acceleration time (PAT), pulmonary ejection time (PET), and tricuspid annular plane systolic excursion (TAPSE). We found that, in these models, RVFWT significantly increased, but RVFAC, PAT, or PAT/PET ratios and TAPSE values significantly decreased. Accurate and complete TAPSE patterns were demonstrated in the three rodent models of PH. The RV echocardiography data matched the corresponding invasive hemodynamic and heart histologic data in each model. This serves as a reference study for real‐time and non‐invasive evaluation of RV function in rodent models of PH using echocardiography.

2 June 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
LRLiyu Ran
Liyu Ran
JLJinglun Liu
Jinglun Liu
HTHideharu Tanaka
Hideharu Tanaka
MHMichael W. Hubble
Michael W. Hubble
THTakyu Hiroshi
Takyu Hiroshi
WHWei Huang
Wei Huang
Background: The use of adrenaline in out‐of‐hospital cardiac arrest (OHCA) patients is still controversial. This study aimed to determine the effects of early pre‐hospital adrenaline administration in OHCA patients. Methods and Results: PubMed, EMBASE, Google Scholar, and the Cochrane Library database were searched from study inception to February 2019 to identify studies that reported OHCA patients who received adrenaline. The primary outcome was survival to discharge, and the secondary outcomes were return of spontaneous circulation, favorable neurological outcome, and survival to hospital admission. A total of 574 392 patients were included from 24 studies. The use of early pre‐hospital adrenaline administration in OHCA patients was associated with a significant increase in survival to discharge (risk ratio [RR], 1.62; 95% CI, 1.45–1.83; P <0.001) and return of spontaneous circulation (RR, 1.50; 95% CI, 1.36–1.67; P <0.001), as well as a favorable neurological outcome (RR, 2.09; 95% CI, 1.73–2.52; P <0.001). Patients with shockable rhythm cardiac arrest had a significantly higher rate of survival to discharge (RR, 5.86; 95% CI, 4.25–8.07; P <0.001) and more favorable neurological outcomes (RR, 5.10; 95% CI, 2.90–8.97; P <0.001) than non‐shockable rhythm cardiac arrest patients. Conclusions: Early pre‐hospital administration of adrenaline to OHCA patients might increase the survival to discharge, return of spontaneous circulation, and favorable neurological outcomes. Registration: URL: https://www.crd.york.ac.uk/PROSPERO ; Unique identifier: CRD42019130542.

28 February 2019 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
DLDan Li
Dan Li
XZXiaofang Zeng
Xiaofang Zeng
YHYi Huang
Yi Huang
HLHan Lei
Han Lei
GLGe Li
Ge Li
WHWei Huang
Wei Huang

1 January 2019 in Pulmonary Circulation
Verified
Journal Article
Open access
WWWuwan Wang
Wuwan Wang
XHXiankang Hu
Xiankang Hu
WLWeitin Liao
Weitin Liao
WRW.H. Rutahoile
W.H. Rutahoile
DMDavid J. Malenka
David J. Malenka
WHWei Huang
Wei Huang
No previous meta‐analysis has evaluated the efficacy and safety of pulmonary vasodilators in Fontan physiology. Recent relative trials have obtained conflicting results regarding improvements in peak oxygen consumption; the relatively small number of patients in each study may be a limiting factor. We aimed to evaluate the efficacy and safety of pulmonary vasodilators in Fontan patients. Relevant studies were identified by searching the PubMed, Embase, and Cochrane Library databases. Pooled outcomes were determined to assess the efficacy and safety of pulmonary vasodilators in Fontan patients. Nine randomized controlled studies involving 381 patients with Fontan circulation were included. Pulmonary vasodilator therapy led to significant improvement (mean difference = −0.39, 95% CI: [−0.72, −0.05]) in the New York Heart Association (NYHA) functional class. The 6‐minute walking distance (6MWD) was significantly increased by 134 m (95% CI: [86.07, 181.94]), and the peak VO2 was also significantly improved (mean difference = 1.42 ml·(kg·min)‐1, 95% CI: [0.21, 2.63]). Additionally, the mean pulmonary artery pressure (mPAP) was significantly reduced (mean difference = −2.25 mmHg, 95% CI: [−3.00, −1.50]). No significant change was found in mortality or in brain natriuretic peptide (BNP) or N‐terminal pronatriuretic peptide (NT‐proBNP). Four studies reported no side effects and good drug tolerance, and two studies reported mild adverse effects. The present meta‐analysis indicated that pulmonary vasodilators (primarily the PDE‐5 inhibitor and endothelin‐1 receptor antagonist) significantly improved the hemodynamics of Fontan patients, reduced the NYHA functional class and increased the 6MWD. The peak oxygen consumption was also improved. No significant change was observed in mortality or in the BNP or NT‐proBNP level. Overall, the pulmonary vasodilators were well tolerated. This finding needs to be confirmed in future studies.

10 September 2021 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
XJXin Jiang
Xin Jiang
YZYong-Jian Zhu
Yong-Jian Zhu
YZYu-Ping Zhou
Yu-Ping Zhou
FPFu-Hua Peng
Fu-Hua Peng
LWLan Wang
Lan Wang
Zhi-Cheng JingZhi-Cheng Jing
Zhi-Cheng Jing
This study aimed to assess the clinical characteristics and long-term survival outcome in patients with Takayasu’s arteritis-associated pulmonary hypertension (TA-PH). We conducted a nationally representative cohort study of TA-PH using data from the National Rare Diseases Registry System of China. Patients with pulmonary artery involvement who fulfilled the diagnostic criteria of Takayasu’s arteritis and pulmonary hypertension were included. The primary outcome was the time from diagnosis of TA-PH to the occurrence of all-cause death. Between January 2007 and January 2019, a total of 140 patients were included, with a mean age of 41.4 years at diagnosis, and a female predominance (81%). Patients with TA-PH had severely haemodynamic and functional impairments at diagnosis. Significant improvements have been found in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and haemodynamic profiles in patients with TA-PH receiving drugs approved for pulmonary arterial hypertension. The overall 1-, 3-, and 5-year survival rates in TA-PH were 94.0%, 83.2%, and 77.2%, respectively. Predictors associated with an increased risk of all-cause death were syncope [adjusted hazard ratio (HR) 5.38 (95% confidence interval 1.77–16.34), P = 0.003], NT-proBNP level [adjusted HR 1.04 (1.03–1.06), P < 0.001], and mean right atrial pressure [adjusted HR 1.07 (1.01–1.13), P = 0.015]. Patients with TA-PH were predominantly female and had severely compromised haemodynamics. More than 80% of patients in our cohort survived for at least 3 years. Medical treatment was based on investigators’ personal opinions, and no clear risk-to-benefit ratio can be derived from the presented data.

1 March 2019 in Medicine
Verified
Journal Article
Open access
YXYajie Xiang
Yajie Xiang
WSWenhai Shi
Wenhai Shi
ZLZhuolin Li
Zhuolin Li
YYYunjing Yang
Yunjing Yang
SWStephen Yishu Wang
Stephen Yishu Wang
WHWei Huang
Wei Huang
Background: Recent studies have shown the efficacy for using spironolactone to treat heart failure with reduced ejection fraction (HFrEF), but the efficacy of spironolactone for heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) is unclear. This meta-analysis investigated the efficacy and safety of spironolactone in patients with HFmrEF and HFpEF. Methods and results: We searched several databases including PubMed and the Cochrane Collaboration, for randomized controlled trials (RCTs) that assessed spironolactone treatment in HFmrEF and HFpEF. Eleven RCTs including 4539 patients were included. Spironolactone reduced hospitalizations (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.73–0.95; P = .006), improved New York Heart Association functional classifications (NYHA-FC) (OR, 0.35; 95% CI, 0.19–0.66; P = .001), decreased the levels of brain natriuretic peptide (BNP) (mean difference [MD], − 44.80 pg/mL; 95% CI, −73.44–−16.17; P = .002), procollagen type I C-terminal propeptide (PICP) (MD, −27.04 ng/mL; 95% CI, −40.77–−13.32, P < .001) in HFmrEF and HFpEF. Besides, it improved 6-minute walking distances (6-MWD) (standard weighted mean difference [SMD], 0.45 m; 95% CI, 0.27–0.64; P < .001), decreased amino-terminal peptide of procollagen type-III (PIIINP) (SMD, −0.37 μg/L; 95% CI, −0.59–−0.15; P = .001) in HFpEF only. The risks of hyperkalemia (P<.001) and gynecomastia (P<.001) were increased. Conclusion: Patients with HFmrEF and HFpEF could benefit from spironolactone treatment, with reduced hospitalizations, BNP levels, improved NYHA-FC, alleviated myocardial fibrosis by decreasing serum PICP in HFmrEF and HFpEF, decreased PIIINP levels and increased 6-MWD only in HFpEF. The risks of hyperkalemia and gynecomastia were significantly increased with the spironolactone treatment.